


PHARMACEUTICAL 2022



IntelGenx Technologies Corp. Rank 378 of 466





PHARMACEUTICAL 2022



IntelGenx Technologies Corp. Rank 378 of 466

The relative strengths and weaknesses of IntelGenx Technologies Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IntelGenx Technologies Corp. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 60% points. The greatest weakness of IntelGenx Technologies Corp. is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -18%, being 96% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	11,437
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,020
Liabilities, Non-Current	642
Other Assets	1,255
Other Compr. Net Income	-515
Other Expenses	3,041
Other Liabilities	6,372
Other Net Income	-1,336
Other Revenues	1,535
Property and Equipment	5,213
Research and Development	2,717
Selling, General and Administrative Expense	3,753

Output Variable	Value in 1000 USD
Assets	17,905
Liabilities	14,034
Expenses	9,511
Revenues	1,535
Stockholders Equity	3,871
Net Income	-9,312
Comprehensive Net Income	-9,570
Economic Capital Ratio	-18%

